Merck

ORG Health Care / Pharmaceuticals Momentum 15.2 NORMAL Primary: Spectral Shift

$60.1B revenue (2025), Rahway-based Merck slashed Zepatier pricing on hepatitis C therapy amid generic competition. Shift signals retreat from premium HCV positioning as cure rates saturate developed markets.

Price reduction strategy on Zepatier (sofosbuvir/velpatasvir) hepatitis C treatment; reflects competitive market dynamics and generic/biosimilar pressure in HCV space.
-0.33
PSI Score
15.2
Momentum
1%
Confidence
4
Connections
Connected Entities
Novartis Pfizer Sanofi China European Union Eli Lilly
Watch This Entity
PSI Intelligence
30-Day Trend
2026-03-20 2026-04-19 5 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.136
Narrative Drift
0.000
Spectral Shift
831.349
Sentiment-Momentum Divergence
0.000
Source Concentration
0.977
Peer Comparison
N/A
Sector Rank
+0.00
Peer Z-Score
0%
Sector Percentile
Network Analysis
4 Degree Centrality
Centrality History
2026-03-20 2026-04-19 5 0 Degree Mentions
EntityWeight StatusFirst Seen
Novartis 32 STRENGTHENED
Pfizer 32 STRENGTHENED
Sanofi 4 NEW
China 2 STABLE
European Union 2 STABLE
Eli Lilly 2 NEW
Article Coverage (0)
DateLaneTitle

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-04-19 ← Intelligence Network